BICD2: A Protein with Multiple Roles in Cellular Signaling and Disease

Target Name: BICD2

NCBI ID: G23299

BICD2

BICD2: A Protein with Multiple Roles in Cellular Signaling and Disease

BICD2 (SMALED2A) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of leucine-rich repeat (LRR) proteins, which are characterized by the presence of a specific repeat sequence in the protein sequence.

The BICD2 protein is known for its role in the regulation of mitochondrial function and energy metabolism. It is a key regulator of the mitochondrial translation machinery, which is responsible for the production of proteins from mRNA templates in the mitochondria.

BICD2 is also involved in the regulation of cellular processes that are critical for cell survival, such as cell apoptosis (programmed cell death), cell cycle progression, and inflammation. It is a negative regulator of the nuclear factor of activating transduction (NF-kappa-B), which is a protein that plays a critical role in the regulation of inflammation and cellular responses to stress.

In addition to its role in cellular signaling, BICD2 is also a potential drug target. Researchers have identified several potential BICD2-targeted small molecules that could be used to treat various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the most promising BICD2-targeted small molecules is a compound called BICD2-239, which is a peptide that consists of the first 239 amino acid residues of the BICD2 protein. BICD2-239 was shown to be a potent inhibitor of the NF-kappa-B pathway, which is involved in the regulation of inflammation and cellular responses to stress.

In preclinical studies, BICD2-239 was shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, it was shown to be effective in inhibiting cancer cell growth and to reduce the formation of new blood vessels. in neurodegenerative diseases.

Another potential BICD2-targeted small molecule is a compound called BICD2-763, which is a peptide that consists of the last 76 amino acid residues of the BICD2 protein. BICD2-763 is also shown to be a potent inhibitor of the NF-kappa-B pathway and has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In addition to its potential as a drug target, BICD2 is also a potential biomarker for the diagnosis and prognosis of various diseases. Its expression has been shown to be affected by a variety of cellular and environmental factors, including stress, exercise, and exposure to toxins.

For example, BICD2 expression has been shown to be increased in individuals who have experienced stress, and it has been shown to be reduced in individuals who have certain cardiovascular risk factors. These changes in BICD2 expression can be used as a diagnostic tool for stress- induced cardiovascular disease and as a target for the development of stress-resistant interventions.

Overall, BICD2 is a protein that has important roles in cellular signaling and energy metabolism. Its regulation by small molecules and its potential as a drug target make it an attractive target for the development of new therapies for various diseases. Further research is needed to fully Understand the mechanisms of BICD2 regulation and its potential as a drug target.

Protein Name: BICD Cargo Adaptor 2

Functions: Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non-processive to a highly processive motor in the presence of dynactin. Facilitates and stabilizes the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track) (PubMed:25814576). Facilitates the binding of RAB6A to the Golgi by stabilizing its GTP-bound form. Regulates coat complex coatomer protein I (COPI)-independent Golgi-endoplasmic reticulum transport via its interaction with RAB6A and recruitment of the dynein-dynactin motor complex (PubMed:25962623). Contributes to nuclear and centrosomal positioning prior to mitotic entry through regulation of both dynein and kinesin-1. During G2 phase of the cell cycle, associates with RANBP2 at the nuclear pores and recruits dynein and dynactin to the nuclear envelope to ensure proper positioning of the nucleus relative to centrosomes prior to the onset of mitosis (By similarity)

The "BICD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BICD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets